- Could Americans Get to COVID Herd Immunity by Late Spring?
- Switch to Plant-Based Diet Could Protect Older Women’s Brains
- COVID in Pregnancy Tied to Higher Odds for ‘Preemie’ Delivery
- ‘Night Owls’ Perform Worse at Work, Study Finds
- Pharmacies Will Distribute COVID-19 Vaccines: What You Need to Know
- Coronavirus Antibodies Appear to Stop Reinfection for Months
- AHA News: What’s Safe Once You’ve Had Your COVID-19 Vaccine?
- FDA Review Finds J&J COVID Vaccine Safe, Effective
- Health Highlights: Feb. 24, 2021
- Migraines? Get Moving: Exercise Can Help Curb Attacks
Dulera Inhaler Approved for Asthma
THURSDAY, June 24Merck & Co.’s Dulera inhaler has been approved for people 12 and older whose asthma isn’t controlled with other medication, the company said Thursday in a news release.
Dulera combines a corticosteroid (mometasone furoate) and a long-acting beta agonist (formoterol fumarate). The latter class of drug increases the risk of asthma-related hospitalization in children and teens, Merck said, so Dulera should only be used by people whose asthma isn’t adequately controlled with a different class of drug.
FDA approval of Dulera was based on clinical testing of 12-to-26 weeks among 1,509 people aged 12 and older. The most common adverse reactions included sinus inflammation (sinusitis) and headache.
Dulera isn’t a rescue medication and does not replace a fast-acting inhaler to treat symptoms that begin suddenly, Merck said.
More information
The FDA has more about this drug’s history.
Source: HealthDay
